野尻霉素 | 15218-38-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 野尻霉素
• 英文名称: nojirimycin
• 英文别名: (3R,4S,5R,6R)-6-(hydroxymethyl)piperidine-2,3,4,5-tetrol
• CAS: 15218-38-9
• 化学式: C₆H₁₃NO₅
• 分子量: 179.173
• InChiKey: BGMYHTUCJVZIRP-GASJEMHNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  113
• 氢给体数：
  6
• 氢受体数：
  6

安全信息

• 海关编码：
  2922399090

反应信息

• 作为反应物：
  描述：

  野尻霉素 在 platinum(IV) oxide 氢气 作用下， 以 乙醇 、 水 为溶剂， 反应 18.0h， 以97%的产率得到1-脱氧野尻霉素
  参考文献：
  名称：

  全合成冯诺吉霉素

  摘要：

  诺奇霉素的全合成

  DOI：

  10.1002/hlca.19820650403
• 作为产物：
  描述：

  野尻霉素-1-磺酸 生成 野尻霉素
  参考文献：
  名称：

  Ptactical Synthesis of Nojirimycin

  摘要：

  DOI：

  10.3987/com-87-4352

文献信息

• CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20160051691A1

  公开（公告）日：2016-02-25

  The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(R N ) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula(I), —P(Z′)(Z″)— or -Linker-R; R is L G , -Linker-L G , or has the structure shown below: L G is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; R N is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.

  本发明提供了包含至少一个式(I)的亚单位的iRNA试剂： 其中： A和B分别独立于每次出现O、N(RN)或S； X和Y分别独立于每次出现H、OH、一个羟基保护基团、一个磷酸基团、一个磷酸二酯基团、一个活化磷酸基团、一个活化亚磷酸基团、一个磷酰胺基团、一个固相支持、-P(Z')(Z″)O-核苷、-P(Z')(Z″)O-寡核苷酸、一个脂质、一个PEG、一个类固醇、一个亲脂物质、一个聚合物、-P(Z')(Z″)O-连接子-OP(Z′″)(Z″″)O-寡核苷酸、一个核苷酸、一个寡核苷酸、-P(Z')(Z″)-式(I)、-P(Z')(Z″)-或-连接子-R； R是LG、-连接子-LG，或具有下面所示结构： LG独立于每次出现的是一种碳水化合物，例如，单糖、双糖、三糖、四糖、寡糖、多糖； RN独立于每次出现的是H、甲基、乙基、丙基、异丙基、丁基或苄基； Z'、Z″、Z′″和Z″″分别独立于每次出现的是O或S。
• [EN] 1,2,4-SUBSTITUERTE 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY<br/>[FR] DERIVES DE 1,2,3,4-TETRAHYDRO- ET 1,2 DIHYDRO-QUINOLEINE ET 1,2,3,4-TETRAHYDRO-QUINOXALINE 1,2,4-SUBSTITUES, UTILES COMME INHIBITEURS DE CETP POUR LE TRAITEMENT DE L'ATHEROSCLEROSE ET DE L'OBESITE
  申请人：PFIZER PROD INC

  公开号：WO2004085401A1

  公开（公告）日：2004-10-07

  Quinoline and quinoxaline compounds of formula I and III wherein the subtituent are as defined in claims 1 and 15, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

  喹啉和喹啉并喹啉化合物的公式I和III，其中取代基如权利要求1和15中所定义的，含有这种化合物的药物组合物以及使用这种化合物来提高某些血浆脂质水平，包括高密度脂蛋白胆固醇，并降低其他一些血浆脂质水平，如LDL胆固醇和甘油三酯，并因此治疗由HDL胆固醇水平低和/或LDL胆固醇和甘油三酯水平高加重的疾病，如动脉粥样硬化和心血管疾病在某些哺乳动物中，包括人类。
• [EN] PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS<br/>[FR] COMPOSES DE PIPERIDINE PHENYLE A SUBSTITUTION PHENYLE S'UTILISANT COMME ACTIVATEURS DE PPAR
  申请人：PFIZER PROD INC

  公开号：WO2004048334A1

  公开（公告）日：2004-06-10

  PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.

  PPARα激动剂，含有这类化合物的药物组合物以及利用这类化合物提高特定血浆脂质水平，包括高密度脂蛋白胆固醇，并降低其他特定血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，并据此治疗由高密度脂蛋白胆固醇水平低和/或低密度脂蛋白胆固醇和甘油三酯水平高加重的疾病，如动脉粥样硬化和心血管疾病，在哺乳动物，包括人类中的应用。
• [EN] RAPAMYCIN CARBOHYDRATE DERIVATIVES<br/>[FR] DERIVES DE RAPAMYCINE CARBOHYDRATE
  申请人：ISOTECHNIKA INTERNAT INC

  公开号：WO2004101583A1

  公开（公告）日：2004-11-25

  This invention provides modified rapamycins that have specific monosaccharide(s), oligosaccharide(s), pseudosugar(s) or derivatives thereof attached through a linker to create rapamycin carbohydrate derivatives having enhanced pharmacokinetic and/or pharmacodynamic profiles. For example, administration of the rapamycin carbohydrate derivative results in altered pharmacokinetic profiles and reduced toxicities. Thus, the present invention provides compounds with characteristics that are distinct from other drugs in its class such as rapamycin.

  这项发明提供了经过改良的雷帕霉素，其具有通过连接剂连接的特定单糖，寡糖，伪糖或其衍生物，从而创造出具有增强药代动力学和/或药效动力学特性的雷帕霉素糖衍生物。例如，给予雷帕霉素糖衍生物的治疗导致了改变的药代动力学特性和降低的毒性。因此，本发明提供了具有与其他同类药物（如雷帕霉素）不同特性的化合物。
• [EN] SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS<br/>[FR] COMPOSES HETEROARYLE ET PHENYLSULFAMOYLE SUBSTITUES
  申请人：PFIZER PROD INC

  公开号：WO2005092845A1

  公开（公告）日：2005-10-06

  The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.

  本发明涉及取代杂环芳基和苯基磺酰胺化合物，含有这种化合物的药物组合物以及将这种化合物用作过氧化物酶增殖激活受体（PPAR）激动剂的用途。PPARα激活剂，含有这种化合物的药物组合物以及使用这种化合物提高特定血浆脂质水平，包括高密度脂蛋白胆固醇，并降低其他特定血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，从而治疗由高密度脂蛋白胆固醇水平低和/或低密度脂蛋白胆固醇和甘油三酯水平高加重的疾病，如动脉粥样硬化和心血管疾病，在哺乳动物，包括人类中。这些化合物还可用于治疗反常能量平衡（NEB）和反常相关疾病的反刍动物。